

TABLE 204: ADVERSE EVENT

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-2	1	(6) SOF12 + LDV12	73	109	67%
		(7) SOF24 + LDV24	88	109	81%
		(10) SOF12 + LDV12 + RBV12	96	111	86%
		(11) SOF24 + LDV24 + RBV24	100	111	90%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	74	95	78%
Bacon et al., 2011 RESPOND2	1	(1) PR48	77	80	96%
		(74) B32 PR36-48 RGT	160	162	99%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	67	77	87%
		(10) SOF12 + LDV12 + RBV12	75	78	96%
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	63	79	80%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	10	10	100%
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	9	9	100%
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	8	9	89%
Forns et al., 2014 PROMISE	1	(1) PR48	125	133	94%
		(42) SIM12 PR24-48 RGT	253	260	97%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	92	103	89%
Jensen et al., 2015 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	393	398	99%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	45	47	96%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	7	19	37%
		(10) SOF12 + LDV12 + RBV12	12	21	57%
Lawitz et al., 2014 COSMOS	1	(5) SIM12 + SOF12	11	14	79%
		(72) SOF12 + SIM12 + RBV12	24	27	89%
Lawitz et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	25	33	76%
		(59) GRZ18 + ELB18 (50 mg q.d.)	26	32	81%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	25	32	78%
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	31	33	94%
Lok et al., 2014 DUAL A2	1b	(17) DCV24 + ASU24	20	20	100%
Lok et al., 2014 QUAD B2	1	(18) DCV24 + ASU24 + PR24	21	21	100%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	167	205	81%
Molina et al., 2015 PHOTON-2	2+3	(4) SOF24 + RBV24	47	55	85%
Pol et al., 2015	1	(40) SOF12 + PR12	71	80	89%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	371	384	97%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
		(68) SIM12 PR48	347	379	92%
Sulkowski et al., 2014-3	2+3	(4) SOF24 + RBV24	37	41	90%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	41	51	80%
Zeuzem et al., 2014 SAPPHERE-II	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	271	297	91%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	126	132	95%
		(39) T12 PR48 q8	260	266	98%
Zeuzem et al., 2014 ASPIRE	1	(1) PR48	63	66	95%
		(68) SIM12 PR48	63	66	95%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q.d. = once daily; RBV = ribavirin; RGT = response-guided therapy; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.